COVID-19 Infection During Pregnancy: A Closer Look at the Risk of Stillbirth

By Staff Writer

November 6, 2023

A Groundbreaking Study

A recent Nordic research study has shed light on the potential increased risk of stillbirth among pregnant women infected with COVID-19. This comprehensive study, the largest of its kind, analysed data from 389,949 births across Norway, Sweden and Denmark. The findings revealed a 2.4 times higher risk of stillbirth among women who contracted COVID-19 during pregnancy.


Understanding the Risks

While stillbirth remains a rare occurrence, the study found that the absolute risk was 2.3 per 100,000 follow-up days for pregnant women without COVID-19. In contrast, the risk was 5.8 per 100,000 follow-up days for those who contracted the virus during pregnancy. Notably, the risk of stillbirth was highest within the first two weeks of infection.

COVID-19 and Pregnancy Risk

The study also discovered that the risk of stillbirth varied based on the COVID-19 variant that the pregnant woman tested positive for. The risk was highest during the period when the Delta variant was dominant. However, due to changes in COVID-19 testing recommendations, the risk associated with current variants remains unknown.

In light of these findings, the Norwegian Institute of Public Health recommends pregnant women get vaccinated against COVID-19 during their second or third trimester. This recommendation is based on research showing a certain increased risk of serious illness or complications among pregnant women infected by COVID-19, with no connected risk for the mother, child, or pregnancy among those vaccinated.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.